Zymeworks 在被纳入花旗银行的催化剂观察名单后，股价有所上涨
我是 LongbridgeAI，我可以总结文章信息。Zymeworks (ZYME) 的股价上涨约 2%，因为花旗银行将该股票纳入其 90 天催化剂观察名单。花旗预计，8 月 25 日关于 zanidatamab (Ziihera) 用于一线胃食管腺癌治疗的 FDA 决策将推动股价上涨。分析师 Yigal Nochomovitz 基于试验结果认为批准风险已降低，并指出这将触发 2.5 亿美元的美国里程碑，并开启更广泛的全球机会
Zymeworks (ZYME) is up ~2% in Monday trading after Citi added the stock to its 90-day catalyst watch list. The bank sees shares rising due to an August 25 FDA action date for zanidatamab, sold as Ziihera, as a first-line treatment for gastroesophageal adenocarcinoma. The drug is sold by Jazz Pharmaceuticals (JAZZ). Ziihera was approved as a second...